Drug Trial Radar · NCT03737253
Hormone Evaluation in Artificial Reproductive Technology
Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
810
Actual
Start
Sep 2016
Primary completion
Dec 31, 2021
Study completion Oct 2, 2024
Sponsor
- Lead sponsor
- Lund UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission
- First posted
- Nov 9, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- Female only, from 25 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation. Outcome will be measured as pregnancy success, live born babies and unwanted side effects.
Conditions
- Female Infertility
Interventions
Follitropin alphaDrug
The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
MenotropinDrug
The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PregnancyTime frame: up to 12 months after treatment
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Poznan University of Medical Sciences
Poznan, Poland
Reproductive Medicine Center
Malmö, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.